Itchiness as a Side Effect of Neuraxial Anesthesia

Itchiness, or pruritus, is a common and often troublesome side effect of neuraxial anesthesia, particularly when opioids are administered via epidural or intrathecal routes. This phenomenon has been well-documented in medical literature and can significantly impact patient comfort and satisfaction during the postoperative period. Understanding the mechanisms, prevalence, and management strategies for neuraxial opioid-induced pruritus is crucial for anesthesiologists and other healthcare providers involved in perioperative care.

The incidence of itchiness following opioid administration in neuraxial anesthesia varies widely depending on the specific opioid used, the route of administration, and patient factors. According to a comprehensive review of 52 reports, the overall incidence of itching was found to be 8.5% in patients receiving epidural opioids and 46% in those receiving spinal opioids . This marked difference in prevalence highlights the importance of considering the route of administration when assessing the risk of this side effect.

The onset and duration of pruritus can vary based on the pharmacokinetics of the opioid used. Lipid-soluble opioids such as fentanyl and sufentanil typically cause shorter-duration itching, while intrathecal morphine can lead to more prolonged symptoms. The timing of onset also differs, with intrathecal administration resulting in almost immediate peak concentrations in the cerebrospinal fluid, whereas epidural administration may have a delayed onset of 10-20 minutes for fentanyl and 1-4 hours for morphine.

The mechanism underlying itchiness due to neuraxial opioid anesthesia is complex and not fully understood. However, current evidence suggests that it involves the activation of μ-opioid receptors in the spinal cord, particularly in the dorsal horn. This activation may lead to the disinhibition of “itch-selective” neurons in the lamina I spinothalamic tract, resulting in the sensation of itching without direct stimulation of peripheral nerves. Interestingly, while μ-opioid receptor activation promotes itching, κ-opioid receptors appear to suppress it, suggesting a potential avenue for therapeutic intervention.

The distribution of pruritus following neuraxial opioid administration is often characteristic. Many patients experience a segmental pattern of itching centered around the level of injection. In some cases, the itching may be localized to specific areas such as the nose and face. This segmental distribution further supports the hypothesis of a spinal cord-mediated mechanism rather than a systemic effect.

Management of neuraxial opioid-induced pruritus can be challenging. While many cases are mild and self-limiting, some patients experience severe itchiness that can be more distressing than pain itself. Various pharmacological interventions have been studied, with mixed results. Naloxone, an opioid antagonist, has shown efficacy in treating pruritus but may also reverse the analgesic effects of the opioid. Ondansetron, a 5-HT3 receptor antagonist commonly used for nausea and vomiting, has demonstrated promising results in managing opioid-induced pruritus. A randomized, double-blind, placebo-controlled study found that 8 mg of intravenous ondansetron effectively treated pruritus induced by spinal or epidural morphine.

Itchiness as a side effect of neuraxial anesthesia, particularly when opioids are used, remains a significant clinical challenge. With incidence rates as high as 46% for spinal opioids, it is a

common issue that can impact patient comfort and satisfaction. Understanding the mechanisms involved and the available treatment options is essential for optimal perioperative management. As research continues, new strategies for prevention and treatment may emerge, potentially improving the overall experience for patients receiving neuraxial anesthesia.

References

1. Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain. 1988;33(2):149-160. doi:10.1016/0304-3959(88)90085-1.

2. Kumar K, Singh SI. Neuraxial opioid-induced pruritus: An update. J Anaesthesiol Clin Pharmacol. 2013;29(3):303-307. doi:10.4103/0970-9185.117045.

3. Szarvas S, Harmon D, Murphy D. Neuraxial opioid-induced pruritus: a review. J Clin Anesth. 2003;15(3):234-239. doi:10.1016/s0952-8180(02)00501-9.

4. Charuluxananan S, Somboonviboon W, Kyokong O, Nimcharoendee K. Ondansetron for treatment of intrathecal morphine-induced pruritus after cesarean delivery. Reg Anesth Pain Med. 2000;25(5):535-539. doi:10.1053/rapm.2000.7527.

5. Bonnet MP, Marret E, Josserand J, Mercier FJ. Effect of prophylactic 5-HT3 receptor antagonists on pruritus induced by neuraxial opioids: a quantitative systematic review. Br J Anaesth. 2008;101(3):311-319. doi:10.1093/bja/aen202.